Views Expressed Disclaimer:

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.

Highlights

• The stock rose 10.26% over the past month on NSE.
• Dr. Reddy’s acquired Progynova® and Cyclo-Progynova® trademarks in India.
• Progynova® recorded sales of about ₹ 100 crore, per IQVIA MAT Dec 2025.

Shares of Dr Reddy's Laboratories Ltd (NSE:DRREDDY) traded at ₹ 1,287.00 on 19 February, up ₹ 6.70 or 0.52% the time of writing. Over the past five days, the stock gained ₹ 16.20, reflecting a 1.27% increase.

On a one-month basis, DRREDDY advanced ₹ 119.80, translating into a 10.26% rise. Over six months, the stock moved higher by ₹ 42.80 or 3.44%. Year-to-date, it has added ₹ 33.60, up 2.68%.

In the past year, shares climbed ₹ 121.15, marking a 10.39% increase. Over a five-year period, the stock appreciated ₹ 352.21, representing a 37.62% gain.

Entry into Hormone Replacement Therapy Segment
Dr. Reddy's Laboratories Ltd has entered the hormone replacement therapy (HRT) segment in India through the acquisition of trademarks and related assets of Progynova® and Cyclo-Progynova® from Mercury Pharma Group Limited.

Progynova® (estradiol valerate) is prescribed for managing symptoms linked to estrogen deficiency and for prevention of postmenopausal osteoporosis. Cyclo-Progynova® combines estradiol valerate with norgestrel, offering both estrogen and progestogen components for women who require combination therapy.

These brands have established recognition among physicians in India. Progynova® leads the estradiol market segment and, according to IQVIA MAT December 2025 data, recorded sales of around ₹ 100 crore.

Expansion in Women’s Health Portfolio
The acquisition adds to Dr. Reddy’s presence in the gynaecology segment and marks an expansion into the HRT category. The company plans to leverage its distribution network and market access across India to extend the reach of these therapies and improve patient access.

The move aligns with its ongoing focus on expanding its women’s health portfolio in India and emerging markets.

Broker Consensus Signals Upside with Hold Stance
According to Refinitiv data as of 19 Feb 2026, Analysts maintain a neutral outlook on Dr. Reddy's Laboratories Ltd., with the current consensus recommendation at 2.76 (HOLD). The average target price stands at INR 1,328.65, indicating a modest potential upside of approximately 3.09% from current levels.

While the company benefits from its strong presence in generics and specialty pharmaceuticals, the relatively low long-term growth (LTG) estimate of 1.70% suggests measured earnings expansion ahead. Overall, broker sentiment reflects stability in operations but limited near-term re-rating potential.

Dr Reddy's Laboratories has recorded steady gains across multiple time frames, including a 10.26% rise over the past month. The acquisition of Progynova® and Cyclo-Progynova® marks its entry into India’s HRT segment, where Progynova® reported sales of about ₹ 100 crore as of December 2025. Market participants are observing how the integration of these brands influences the company’s position in the gynaecology and women’s health space.

FAQs

Q1. How has DRREDDY stock performed recently?
DRREDDY rose 0.52% on 19 February and gained 10.26% over the past month on the NSE.

Q2. What brands has Dr. Reddy’s acquired in the HRT segment?
The company acquired the trademarks and related assets of Progynova® and Cyclo-Progynova® in India.

Q3. What were Progynova® sales as per latest available data?
According to IQVIA MAT December 2025 data, Progynova® recorded sales of around ₹ 100 crore.